Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.42 |
| ▸ | MGMT | P16455 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938155 | 0.82 | BRD4 (0.40) | LMNAMETAP2METAP1HDAC6KMT2A | |
| SCHEMBL14102460 | 0.81 | L3MBTL1 (0.42) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL2939763 | 0.79 | MGMT (0.45) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL2930276 | 0.79 | CDK1 (0.62) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL16852189 | 0.78 | KMT2A (0.47) | LMNAMETAP2METAP1HDAC6KMT2A | |
| SCHEMBL4845428 | 0.77 | POLB (0.47) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL9681378 | 0.76 | TRPA1 (0.43) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| 6-O-Benzylguanine SCHEMBL29405347 | 0.74 | MGMT (0.63) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| 6-O-Benzylguanine SCHEMBL600698 | 0.74 | MGMT (0.63) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL821881 | 0.73 | CDK1 (0.46) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
| EP-1925675-B1 | Process for production of nucleoside compound | MITSUI CHEMICALS INC (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-1338654-B1 | PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND | MITSUI CHEMICALS INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7381820-B2 | α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside | YAMASA CORPORATION (JP) | 2008-06-03 | — | — | US | disclosed |
| EP-1178051-B1 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | MITSUI CHEMICALS INC (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1925675-A1 | Process for production of nucleoside compound | Mitsui Chemicals, Inc. (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20070135627-A1 | Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside | KOHEL YAMADA, ETAL | 2007-06-14 | — | — | US | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1177202-A1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2002-02-06 | — | — | EP | disclosed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6291670-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| WO-2000069876-A1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069877-A1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
| US-6103707-A | TREATMENT OF HERPES SIMPLEX VIRUS 1 (HSV-1), HERPES SIMPLEX VIRUS 2 (HSV-2), HUMAN CYTOMEGALOVIRUS (HCMV) AND VARICELLA-ZOSTER VIRUS | YAMASA CORPORATION (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-0839813-A1 | 9-(2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSYL)PURINE DERIVATIVES | YAMASA CORPORATION (JP) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | CDK1 447/4885CCNB1 74/4885CCNA2 73/4885 |
| US-20070135627-A1 | Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside | TYMP, PNP, DUT | CDK1 305/4885CCNB1 150/4885CCNA2 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.